insulin-like growth factor 1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-17. Numbers and descriptions here follow the published literature rather than marketing material.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Routine purity assay | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Liquid chromatography–mass spectrometry | Mass shift reveals modification or truncation |
| Typical purity specification | Greater than 95 percent | Reported as main-peak area percentage |
| Long-term storage | Minus 20 degrees Celsius or colder | Sealed, protected from light |
| Principal degradation routes | Oxidation, deamidation, aggregation | Monitored individually during stability studies |
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
In 1470, one of these weavers, known in France as Jean Le Calabrais, invented the prototype of a Jacquard-type loom. It was able to work the yarns faster and more precisely. Charles V of Spain formally recognized the growth of the silk industry of Catanzaro in 1519 by allowing the city to establish a consulate of the silk craft, charged with regulating and checking the various stages of production. At the time, the city declared that it had over 500 looms. By 1660, when the town had about 16,000 inhabitants, its silk industry ran 1,000 looms, and employed at least 5,000 people. The silk textiles of Catanzaro were sold at the kingdom's markets and were exported to Venice, France, Spain and England. Entire communities of Albanians migrated to towns in northern Calabria, called by the king of Naples in recognition of the services that Albanian leader Gjergj Kastrioti Skanderbeg had rendered to the crown against the Angevins. After 1478 the sovereign allowed these refugees fleeing the Turkish advance in Albania after Skanderbeg's demise to occupy abandoned villages to repopulate them, granting them royal privileges and franchises: hence the Arbëreshë community was born. In the 16th century, Calabria was characterized by demographic and economic development, driven by increasing demand for silk products. After the relative pacification, Calabria followed the historical and political events of the Kingdom of Naples, enduring struggles between France and Spain, for territorial control of the Italian peninsula.
== Career == Knudsen began work as a scientist at the pharmaceutical company Novo Nordisk in Denmark in 1989. As of December 2015, she was being referred to as Scientific Vice President for Global Research at Novo-Nordisk. She served as an adjunct faculty member at Aarhus University from 2015–2020, as a professor in translational medicine. Knudsen has been employed as a Chief Scientific Advisor in Research and Early Development at Novo Nordisk.
=== Short-loop feedback === Prolactin itself provides negative short-loop feedback by acting on long-form prolactin receptors (PRLR) expressed on TIDA neurons, activating the JAK2–STAT5B signalling cascade. This feedback has two temporal components. Within minutes, prolactin switches TIDA neurons from phasic to tonic firing, increasing dopamine release into the portal vasculature. Over 12–16 hours, prolactin increases tyrosine hydroxylase expression and activity, elevating dopamine synthesis. In PRLR-knockout mice, dopaminergic input to the pituitary is markedly reduced despite severe hyperprolactinaemia, confirming that TIDA tone depends on prolactin feedback.
== Composition == The military was mostly composed of white South Africans, who alone were subject to conscription. The permanent force of the Army was 85% Afrikaans speaking. However, black South Africans were the second largest group, and Asians and Coloured citizens with mixed ancestry were eligible to serve as volunteers, several attaining commissioned rank. From 1971 onwards, several black battalions were raised in the Infantry and Service Corps on a tribal basis, most black soldiers serving in these exclusive tribal battalions, which had black NCOs but white commissioned officers. The first black personnel were accepted into commissioned ranks only from 1986, and then only for serving black soldiers and NCOs. The regular Commission would not be open for Bantus until 1991, and then again they would serve only in black units or Support/Service Support units, to avoid having position of authority over white combat arms personnel. The first black officer to be promoted to lieutenant colonel rank and have command over a battalion sized unit was appointed in February 1994. However, black officer candidates from the various Homeland Forces and from South West Africa/SWATF had been accepted since 1981. Units such as the 32 Battalion incorporated many black volunteers, as did the 101 Battalion. Conscription was opposed by organisations such as the End Conscription Campaign, but overall, white morale remained high—as indicated by the few recruits tried for serious disciplinary offences.
Sources: en.wikipedia.org
=== Off-targeting === Off-targeting is another challenge to the use of siRNAs as a gene knockdown tool. Here, genes with incomplete complementarity are inadvertently downregulated by the siRNA (in effect, the siRNA acts as a miRNA), leading to problems in data interpretation and potential toxicity. This, however, can be partly addressed by designing appropriate control experiments, and siRNA design algorithms are currently being developed to produce siRNAs free from off-targeting. Genome-wide expression analysis, e.g., by microarray technology, can then be used to verify this and further refine the algorithms. A 2006 paper from the laboratory of Anastasia Khvorova implicates 6- or 7-basepair-long stretches from position 2 onward in the siRNA matching with 3'UTR regions in off-targeted genes. The tool of siRNA off-target prediction is available at http://crdd.osdd.net/servers/aspsirna/asptar.php and published as ASPsiRNA resource.
=== Host immune response === Epithelial cells express many genes that encode immune mediators and proteins involved in cell-cell communication with hematopoietic immune cells. The resulting immune functions of these non-hematopoietic, structural cells contribute to the mammalian immune system ("structural immunity"). Relevant aspects of the epithelial cell response to infections are encoded in the epigenome of these cells, which enables a rapid response to immunological challenges.
Since the introduction of medicines for the management of obesity in the 1930s, many compounds have been tried. Most of them reduce body weight by small amounts, and several of them are no longer marketed for obesity because of their side effects. Out of 25 anti-obesity medications withdrawn from the market between 1964 and 2009, 23 acted by altering the functions of chemical neurotransmitters in the brain. The most common side effects of these drugs that led to withdrawals were mental disturbances, cardiac side effects, and drug abuse or drug dependence. Deaths were reportedly associated with seven products. Six medications for long-term use are: liraglutide, naltrexone/bupropion, orlistat, semaglutide, tirzepatide and phentermine/topiramate. There is no information on how these drugs affect longer-term complications of obesity such as cardiovascular disease or death, although studies on semaglutide have shown cardiovascular benefits. After stopping treatment with GLP-1 agonists such as semaglutide, liraglutide and tirzepatide, people regain on average more than half (50–70%) of the lost weight within 1 year. In 2019 a systematic review compared the effects on weight of various doses of fluoxetine (60 mg/d, 40 mg/d, 20 mg/d, 10 mg/d) in obese adults. When compared to placebo, all dosages of fluoxetine appeared to contribute to weight loss but lead to increased risk of experiencing side effects such as dizziness, drowsiness, fatigue, insomnia and nausea during period of treatment. However, these conclusions were from low certainty evidence.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.
Removing water slows hydrolysis and limits the mobility that drives aggregation. A dry powder is also less hospitable to microbial growth. These factors make cold storage of the solid form more forgiving than storage of a reconstituted solution.
Methionine oxidation, asparagine and glutamine deamidation, and non-covalent or covalent aggregation are the main routes reported for peptides of this class. Each is tracked as a separate impurity. Their relative abundance depends on formulation and storage history.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.